In our study, we classified eight samples as type II LCNEC with the required TP53 mutation, and any one of the following alterations: (1) RB1 loss‐of‐function mutation, (2) MYC/MYCN amplification and (3) NOTCH family (NOTCH1/2/4) mutations (Figure. 5A). The gene discussed is MYCN; the disease is large cell neuroendocrine carcinoma.